MedTrace Logo

Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms

NCT05315856 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-04-07

No results posted yet for this study

Summary

Analysis of humoral antibody and cytokine kinetics after vaccination with either BNT162b2 or ChAdOx1 nCoV-19 vaccine and factors influencing the vaccine immunogenicity

Conditions

  • COVID-19 Vaccination
  • Inflammation
  • Vaccine Immune Response
  • Vaccine Adverse Reaction

Interventions

BIOLOGICAL

either BNT162b2 or ChAdOx1 vaccine

Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.

Sponsors & Collaborators

  • Ajou University School of Medicine

    collaborator OTHER

  • Hallym University Kangnam Sacred Heart Hospital

    collaborator OTHER

  • Korean Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • Korea University Guro Hospital

    lead OTHER

Principal Investigators

  • Joon Young Song, MD · Korea University Guro Hospital

  • Jung Yeon Heo, MD · Ajou University School of Medicine

  • Yu Bin Seo, MD · Hallym University Kangnam Sacred Heart Hospital

Eligibility

Min Age
19 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-05-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05315856 on ClinicalTrials.gov